Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q12899
UPID:
TRI26_HUMAN
Alternative names:
Acid finger protein; RING finger protein 95; Zinc finger protein 173
Alternative UPACC:
Q12899; A6NG96; Q5SRL2
Background:
Tripartite motif-containing protein 26, also known as Acid finger protein, RING finger protein 95, and Zinc finger protein 173, plays a pivotal role in immune response and DNA repair. It regulates IFN-beta production, oxidative stress responses, and antiviral mechanisms, impacting DNA glycosylases NEIL1, NEIL3, and NTH1 levels. It also influences LPS-mediated inflammatory responses and ferroptosis by ubiquitinating various proteins for degradation.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 26 could open doors to potential therapeutic strategies.